CD274 and small cell lung carcinoma: IP/IC plus camrelizumab showed better PFS than EP/EC plus PD-L1 as first-line treatment in patients with ES-SCLC (HR=0.58, 95% CI 0.42-0.81; P=0.0013) (Figure 1).